CD5+CD19+ CLL cells increased following treatment with ruxolitinib (C6D21 and C7D21) and then decreased during the 2‐week period off ruxolitinib (C7D1) (Figure 2B). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.